AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02145871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluid management guided by the EV1000
Study NCT01958853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RINCE
Description: The NeuroPoint device is used to deliver repeat applications of RINCE therapy
Study NCT02961049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photoactivated
Description: Photoactivated for 20 seconds
Study NCT02117635 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX DP
Description: 20 million cell dose administered by surgery to the damaged area of the brain
Study NCT01394887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 850 mg of metformin twice daily over 12 weeks
Study NCT01394887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 850 mg gel capsules with starch (6.8 calories)as placebo
Study NCT01480011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lactobacillus CD2 lozenges
Description: The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
Study NCT02715726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02715726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for alirocumab
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02715726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe
Description: Pharmaceutical form:capsule Route of administration: oral
Study NCT02715726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for ezetimibe
Description: Pharmaceutical form:capsule Route of administration: oral
Study NCT02715726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02715726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02715726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02715726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02715726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02715726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT01448005 — intervention group
Intervention type: DEVICE
Intervention: wearable defibrillator (LifeVest)
Description: A wearable defibrillator automatically detects and treats ventricular tachycardia and ventricular fibrillation without the need for bystander intervention.
Study NCT00797238 — intervention group
Intervention type: OTHER
Description: No intervention in this study
Study NCT02360293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stay Strong w/coaching
Description: Pts randomly placed in the Stay Strong w/coaching group receive an app-mediated physical activity intervention. Pts are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly and will receive tailored push notifications. Each week the pt will receive a new automatically calculated personalized physical activity goal. Stay Strong coaches will call pts up to 3 times in the first 6-8 weeks of the study to help pts meet physical activity goals including problem solving support. Pts will also be reminded to follow-up with their healthcare provider as needed for the remainder of the 12-month program.
Study NCT02360293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stay Strong
Description: Pts randomly placed in the Stay Strong arm are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly. Pts will have access to a standard app-mediated intervention that is linked to the wearable device.
Study NCT02410265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lantern: Guided self-help program
Description: Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call.
Study NCT02410265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health Online: Self-help program
Description: Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
Study NCT01859845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: Our team of dermatologists and biomechanical engineers led by the PI developed a simulation skills training prototype device using a smartphone. Software was developed to teach dermoscopic evaluation of pigmented lesions using the three-poin checklist of dermoscopy. The software used in the smartphone presentation of the educational intervention also provides a decision tree of clinical management options and best-practices feedback. No patients are involved in this research.
Study NCT00895960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dose of 150 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
Study NCT00895960 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT (Radiotherapy)
Description: As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).
Study NCT00895960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ (Temozolomide)
Description: 75 mg/m\^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m\^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m\^2 daily of subsequent cycles.
Study NCT05462808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High viscosity glass ionomer cement
Description: High viscosity glass ionomer cement
Study NCT03146845 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Care
Description: Foam Dressing
Study NCT02652845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Engagement Program
Description: This intervention is an evidence based and community informed program designed to stimulate physical activity and increase healthy food choices among participants. The intervention includes weekly lessons, personal support in the form of biweekly check in calls with a peer support coach and weekly physical activity and nutrition classes.
Study NCT02322645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone Tablets 3 mg
Study NCT02322645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone Tablets 3 mg
Study NCT02203656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo supplement
Study NCT02203656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo supplement
Study NCT02203656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: protein supplement
Study NCT02203656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-home exercise
Description: In-home exercise program
Study NCT01680835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EverFlex™ Self-Expanding Peripheral Stent System
Description: Using the EverFlex™ Self-Expanding Peripheral Stent System to treat atherosclerotic superficial femoral artery (SFA) and proximal popliteal lesions 4-18 cm long in subjects with Rutherford Clinical Categories 2-4.
Study NCT02291640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: direct laryngoscopy
Study NCT02291640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoPilot
Description: video laryngoscopy
Study NCT01396915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary Protein Intake
Description: Dietary Protein Intake This is a 12-week randomized,prospective study incorporating a dietary intervention in which subjects will consume either higher protein(HP:1.4g protein•kg-1•d-1) or normal protein diet (NP:.8g protein•kg-1•d-1)
Study NCT04335539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: Administered intravenously over 3 hours
Study NCT04335539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care antibiotics will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
Study NCT02646761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterACTION
Description: InterACTION guided home exercise program paired with standard of care physical therapy
Study NCT02646761 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Physical Therapy
Description: Physical therapy rehabilitation program
Study NCT00359801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
Description: Subjects are randomized to use Exubera. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice). Enrolling physicians are provided with the approved local label for Exubera to guide prescribing and treatment decisions.
Study NCT00359801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
Description: Subjects are randomized to use usual diabetes care. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
Study NCT04246827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Lifestyle Weight Management
Description: The Enhanced Lifestyle Weight Management program was a 12-week protocol in which training in coping skills to increase self-efficacy and decrease the impact of RA pain on behavioral (e.g., activity, eating) and psychosocial (e.g., mood, relationships) weight loss factors were integrated into a lifestyle behavioral weight loss intervention.
Study NCT03420586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: The nitrous oxide group (GN2O) will receive 70% N2O in 30% O2 at the end of surgery.
Study NCT03353012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel Drug Implant
Description: Etonogestrel 68 mg (single rod) is implanted at inner arm of participant.
Study NCT03353012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel Drug Implant
Description: Etonogestrel 68 mg (single rod) is implanted at inner arm of participant.
Study NCT03353012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel Drug Implant
Description: Levonorgestrel 75 mg (2 rods) are implanted at inner arm of participant.
Study NCT03353012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Drug Implant
Description: Levonorgestrel 75 mg (2 rods) are implanted at inner arm of participant.
Study NCT00824044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.
Study NCT00678119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-003
Description: Dendritic cell Immunotherapeutic
Study NCT00678119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: An approved drug for the treatment of RCC
Study NCT00861146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral counseling plus contingency management
Description: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum
Study NCT00861146 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral counseling plus contingency management
Description: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum
Study NCT02334007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMWH: Dalteparin
Description: Dalteparin is a low-molecular weight heparin. The dosage used will be 5000 units once daily (administered as a subcutaneous injection). This is an established prophylactic dose used to prevent the incidence of VTE after surgery.
Study NCT02334007 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Upon hospital discharge, half of the patients will be assigned to receive saline placebo injections for up to 35 days after surgery. These injections will have no effect.
Study NCT03593265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUNIX
Description: Motor unit number index in 4 muscles: tibialis anterior, abductor digiti mini, abductor pollicis brevis et deltoideus
Study NCT03238404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NAC group
Description: NAC is the name of a procedure. NAC doesn't mean different interventions are used. Patients in this group need receive this NAC procedure instead of one drug before the gastrectomy and ERAS. The program consists of an intravenous injection of 130 mg/m2 oxaliplatin on day 1, followed by oral administration of 50 mg tegafur gimerac (the name of an anticarcinogen) twice daily on days 1-14, every 3 weeks.
Study NCT03238404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery alone group
Description: Patients will not receive neoadjuvant chemotherapy and they will undergo the gastrectomy and ERAS alone.
Study NCT03216863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation
Description: It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy
Study NCT01887574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: questionnaires given to all patients to assess risk factors and quality of life
Study NCT00496093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine, Polyvalent (23-valent)
Study NCT00488163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Dose escalation from 40 mg to 50 mg of Atomoxetine active treatment.
Study NCT00488163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine
Description: Dose escalation from 40 mg to 50 mg of Atomoxetine active treatment.
Study NCT05462808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stainless steel crown
Description: Stainless steel crown
Study NCT00944463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+simvastatin
Description: Gemcitabine and simvastatin
Study NCT02395718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QDU
Description: Treatment in a QDU. Intervention being fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation (see description QDU arm)
Study NCT02395718 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIM
Description: Treatment at a ward at the DIM. Traditional inward hospitalisation
Study NCT03388619 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate bed with integrated boost
Description: Radiation will be delivered at an escalated dose to areas of recurrent prostate cancer identified on imaging and a reduced dose will be delivered to the entire prostate bed.
Study NCT03388619 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate bed irradiation only
Description: Radiation will be delivered to the prostate bed only.
Study NCT03388619 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole Body Bone Scan
Description: At screening, if required by clinician.
Study NCT00944463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine+Placebo
Description: Gemcitabine plus Placebo
Study NCT01898273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-124-CLR1404
Description: single-dose, intravenous
Study NCT01476566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Peer continuous medical education (CME) groups in general practice will be recruited to a cluster randomised educational intervention study. Participating groups will be randomised either to an intervention- or a control group. A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented. A software will be handed out for installation on participants' practice computers, enabling collection of diagnosis- and prescription-data. The captured data will subsequently be linked to corresponding data from the Norwegian Prescription Database (NorPD).
Study NCT01335035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Study NCT01068262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks
Study NCT01068262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Oral Placebo tablet administered once weekly for 4 consecutive weeks
Study NCT00612508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desogen (ethinyl estradiol and desogestrel)
Description: 1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol
Study NCT00612508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuvaRing (ethinyl estradiol and etonogestrel)
Description: Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
Study NCT03388619 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-NaF PET Imaging
Description: At screening, if required by clinician.
Study NCT00627536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.
Study NCT03388619 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT
Description: Computed tomography of the abdomen and pelvis if clinically indicated at screening, with oral and intravenous contrast.
Study NCT03388619 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mpMRI
Description: mpMRI of the prostate bed at screening and 6 month follow up.
Study NCT02997111 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PFA-100
Description: The PFA-100 will be used to assess platelet function before and after energy drink consumption.
Study NCT03874208 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI sequence
Description: An additional sequence to conventional MRI exam (Diffusion tensor imaging) lasting less than 10 min (depending on the MR scanner type and sequence used).
Study NCT03874208 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: MRI exam
Study NCT04541836 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-PMPBB3
Description: single intravenous injection 5mCi 18F-PMPBB3 per scan
Study NCT01365104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desferrioxamine
Description: intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.
Study NCT00998933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel 1.62%
Description: 5 grams applied topically to upper arms/shoulder and abdomen on Day 1
Study NCT02781038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching intervention
Description: Subjects will receive a pamphlet which describes the relationship between smoking and negative outcomes in fracture healing.
Study NCT00627536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched to avotermin dosage strength